Complex i deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)

Brain

Volumn 132, Issue 6, 2009, Pages 1613-1623

  Flinn, Laura ^a   Mortiboys, Heather ^a   Volkmann, Katrin ^b   Kster, Reinhard W ^b   Ingham, Phillip W ^a   Bandmann, Oliver ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Mitochondria; Parkinsons disease

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; PARKIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ANTISENSE OLIGONUCLEOTIDE; DOPAMINE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ARTICLE; CELL LOSS; CONTROLLED STUDY; EMBRYO; GENE MUTATION; GENETIC ANALYSIS; IN SITU HYBRIDIZATION; MICROSCOPY; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZEBRA FISH; ANIMAL; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SCREENING; ELECTRON MICROSCOPY; EMBRYO DEVELOPMENT; EXON; GENE SILENCING; GENETICS; METABOLISM; METHODOLOGY; MUSCLE MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; RNA SPLICING; SUBSTANTIA NIGRA; SWIMMING; ULTRASTRUCTURE;

ANIMALS; CONSERVED SEQUENCE; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG EVALUATION, PRECLINICAL; ELECTRON TRANSPORT COMPLEX I; EMBRYONIC DEVELOPMENT; EXONS; GENE KNOCKDOWN TECHNIQUES; MICROSCOPY, ELECTRON; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL DISEASES; NEURONS; OLIGONUCLEOTIDES, ANTISENSE; PARKINSON DISEASE; RNA SPLICE SITES; SUBSTANTIA NIGRA; SWIMMING; UBIQUITIN-PROTEIN LIGASES; ZEBRAFISH;

EID: 67649413521     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp108     Document Type: Article

References (44)

1. Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P, Rubinsztein DC. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 2008; 28: 8199-207.
2. Beasley SA, Hristova VA, Shaw GS. Structure of the Parkin in-betweenring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 3095-100.
3. Bretaud S, Allen C, Ingham PW, Bandmann O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 2007; 100: 1626-35.
4. Brette F, Orchard C. Resurgence of cardiac t-tubule research. Physiology (Bethesda) 2007; 22: 167-73.
5. Butcher J. Parkin gene therapy could treat Parkinson's disease. Lancet Neurol 2005; 4: 82. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081-6.
6. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-6.
7. Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 2008; 1: 217-31.
8. Ekker SC, Larson JD. K/d technology in model developmental systems. Genesis 2001; 30: 89-93.
9. Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. Zebrafish as a new animal model for movement disorders. J Neurochem 2008; 106: 1991-7.
10. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008; 105: 11364-9.
11. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003; 100: 4078-83.
12. Higashijima S, Hotta Y, Okamoto H. Visualization of cranial motor neurons in live transgenic zebrafish expressing green fluorescent protein under the control of the islet-1 promoter/enhancer. J Neurosci 2000; 20: 206-18.
13. Holzschuh J, Ryu S, Aberger F, Driever W. Dopamine transporter expression distinguishes dopaminergic neurons from other catecholaminergic neurons in the developing zebrafish embryo. Mech Dev 2001; 101: 237-43.
14. Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B, et al. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002; 277: 28572-7.
15. Kay DM, Moran D, Moses L, Poorkaj P, Zabetian CP, Nutt J, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007; 61: 47-54.
16. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317: 1220-4.
17. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
18. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6: 652-62.
19. Langston JW, Tanner CM, Schule B. Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol 2007; 61: 4-6.
20. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 2002; 99: 10813-8.
21. Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 2007; 113: 253-63.
22. Mortiboys H, Thomas KJ, Koopman WJH, Klaffke S, Abou-Sleiman P, Olpin S, et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008; 64: 555-65.
23. Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogues H, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004; 19: 544-8.
24. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-22.
25. Park HC, Hong SK, Kim HS, Kim SH, Yoon EJ, Kim CH, et al. Structural comparison of zebrafish Elav/Hu and their differential expressions during neurogenesis. Neurosci Lett 2000; 279: 81-4.
26. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157-61.
27. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005; 102: 2174-9.
28. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alphasynuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007-19.
29. Rieger S, Koester RW. Preparation of zebrafish embryos for transmission electron microscopy. Cold Spring Harb Protoc 2007; doi:10.1101/pdb.prot4772.
30. Rink E, Wullimann MF. The teleostean (zebrafish) dopaminergic system ascending to the subpallium (striatum) is located in the basal diencephalon (posterior tuberculum). Brain Res 2001; 889: 316-30.
31. Rink E, Wullimann MF. Connections of the ventral telencephalon and tyrosine hydroxylase distribution in the zebrafish brain (Danio rerio) lead to identification of an ascending dopaminergic system in a teleost. Brain Res Bull 2002a; 57: 385-7.
32. Rink E, Wullimann MF. Development of the catecholaminergic system in the early zebrafish brain: an immunohistochemical study. Brain Res Dev Brain Res 2002b; 137: 89-100.
33. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109.
34. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002; 160: 1655-67.
35. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-5.
36. Sun Z, Gilter AD. Discovery and characterization of three novel synuclein genes in zebrafish. Dev Dyn 2008; 237: 2490-5.
37. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007; 6: 933-8.
38. Szabadkai G, Duchen MR. Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) 2008; 23: 84-94.
39. Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc 2008; 3: 59-69.
40. Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong Lim K, et al. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 2007; 26: 312-22.
41. Wen L, Wei W, Gu W, Huang P, Ren X, Zhang Z, et al. Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish. Dev Biol 2008; 314: 84-92.
42. Woods IG, Schier AF. Targeted mutagenesis in zebrafish. Nat Biotechnol 2008; 26: 650-1.
43. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 2006; 103: 10793-8.
44. Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, Xia XG. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 2007; 3: 242-50.